Levetiracetam (Keppra(R)), developed by UCB, was approved in the U.S. in 1999 as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. It is also approved in several European countries. Lundbeck holds marketing rights to the drug in Canada, where it is under review by the regulatory authorities (1). The drug is also under evaluation for the treatment of neuropathic pain and migraine.
机构:
Cambridge Hlth Alliance, Cambridge, MA 02139 USA
Harvard Univ, Sch Med, Dept Psychiat, Cambridge, MA 02138 USACambridge Hlth Alliance, Cambridge, MA 02139 USA
Givon, Lior
Porter, Steven
论文数: 0引用数: 0
h-index: 0
机构:Cambridge Hlth Alliance, Cambridge, MA 02139 USA
Porter, Steven
Padmanabhan, Bharanidharan
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Div Neurol, Cambridge, MA 02138 USACambridge Hlth Alliance, Cambridge, MA 02139 USA
Padmanabhan, Bharanidharan
论文数: 引用数:
h-index:
机构:
Goren, Jessica
Cohen, Pieter A.
论文数: 0引用数: 0
h-index: 0
机构:
Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USACambridge Hlth Alliance, Cambridge, MA 02139 USA